Fig. 3
Effect of vaccine types on RBD-specific IgG and IgA endpoint titers and AUCs. AUCs (A, C) and endpoint titers (B, D) were calculated from titration curves for IgG (A, B) and IgA (C, D) at 15 days and 7 days post-2nd dose, respectively. Endpoint titers were calculated for available samples from samples from Oxford/AZ (n=17), Moderna (n=16 and 17 for IgA and IgG, respectively), and BioNtech/Pfizer (n=25 and 27 for IgA and IgG, respectively) vaccinated mothers using the positive cut-off value established by pre-pandemic samples (n=13). Kruskal-Wallis test with a Dunn’s post hoc test for multiple comparisons was performed to assess the statistical significance of the differences in the antibody endpoint titer and AUC. Data is presented as individual points in box plots showing the median and max-min values. *p <0.05, **p <0.01, ***p <0.001, and ****p <0.0001